https://www.statcounter.com/counter/counter.js
Web Analytics
Home » Posts tagged with » California
Cutera truSculpt iD body sculpting treatment gets expanded approval in Canada

Cutera truSculpt iD body sculpting treatment gets expanded approval in Canada

Cutera said that Health Canada has expanded approval for its truSculpt iD body sculpting treatment to cover its use for the reduction of circumference of the abdomen and non-invasive lipolysis, which is the permanent removal of fat cells from the body. According to American Society for Aesthetic Plastic Surgery and Medical Insight (MII), noninvasive body sculpting […]

Aytu BioScience to acquire Innovus Pharmaceuticals

Aytu acquisition of Innovus : Colorado-based specialty pharma company Aytu BioScience has agreed to acquire Innovus Pharmaceuticals in a deal worth up to $24 million, as per the latest pharma acquisition news. Headquartered in California, Innovus Pharmaceuticals is an over the counter (OTC) consumer goods and specialty pharmaceutical company. On the other hand, Aytu BioScience […]

Continue reading …
BioMed, University of California open cancer research center in San Diego

The University of California San Diego (UC San Diego) and BioMed Realty have opened the Center for Novel Therapeutics (CNT) – a new cancer research center at the former’s Science Research Park in San Diego, California. The cancer research center in San Diego, which spans 137,500sft, has been developed with an investment of $92 million […]

Continue reading …
Neuropore gets FDA orphan drug designation for NPT520-34 for ALS

Neuropore Therapies has secured orphan drug designation for NPT520-34 from the US Food and Drug Administration (FDA) for the treatment of amyotrophic lateral sclerosis (ALS). The California-based biopharma company said that the orphan drug designation will enable the development of NPT520-34 in the treatment of the debilitating medical condition for which there are not many […]

Continue reading …
AtriCure to acquire Californian medical device company SentreHEART

AtriCure acquisition of SentreHEART : Afib device manufacturer AtriCure has agreed to acquire California-based medical device company SentreHEART in a deal worth up to about $300 million. Based in Ohio, AtriCure makes devices for the treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management. AtriCure’s Isolator Synergy Ablation System is the first and […]

Continue reading …
Kodiak Sciences reports positive KSI-301 phase 1b results

KSI-301 phase 1b results : Kodiak Sciences, a California-based retinal medicines development company, said that a phase 1b clinical trial evaluating its investigational intravitreal anti-VEGF antibody biopolymer conjugate KSI-301 has yielded positive interim results. KSI-301 is being studied in patients with anti-VEGF treatment-naïve neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), and macular […]

Continue reading …
Ligand acquires antigen-discovery company Ab Initio Biotherapeutics

Ligand acquisition of Ab Initio : US biopharma company Ligand Pharmaceuticals has acquired California-based antigen-discovery company Ab Initio Biotherapeutics for $12 million in an all-cash deal, as per the latest pharma acquisition news. According to Ligand Pharmaceuticals, design and preparation of antigen are the first steps required for discovering therapeutic antibodies. The US biopharma company […]

Continue reading …
La Jolla secures FDA orphan status for malaria candidate LJPC-0118

La Jolla Pharmaceutical’s LJPC-0118 (artesunate) has been granted orphan drug designation from the US Food and Drug Administration (FDA) for the treatment of malaria. According to the California-based biopharma company, artesunate – the active pharmaceutical ingredient in LJPC-0118 n two randomized, controlled, clinical studies was shown to be superior to quinine in lowering mortality in […]

Continue reading …
Clover Health launches chronic diseases-focused Clover Therapeutics

California-based healthcare company Clover Health has launched a new research subsidiary, called Clover Therapeutics, which will focus on developing drugs for older adults for the treatment of chronic diseases. Clover Therapeutics has started its journey by signing a research collaboration and license agreement with Roche’s subsidiary Genentech to better understand the genomic factors that increase […]

Continue reading …
US neurobehavioral health company BlackThorn raises $76m to advance AI-driven targeted therapeutics

California-based neurobehavioral health company BlackThorn Therapeutics has raised $76 million through a Series B financing round to advance targeted therapeutics using the next-generation artificial intelligence (AI) technologies. The new investors in BlackThorn Therapeutics are Polaris Partners, Premier Partners, Vertex Ventures HC, and Scripps Research. Existing investors Alexandria Venture Investments, Johnson & Johnson Innovation, Altitude Life […]

Continue reading …
Page 1 of 212